RE:Transcript : Q4 2022 (ONCY) Conference Call March 3, 2023Upon review of this 'supposed' Yahoo transcript of the Q1'23 Investors Conference Call, and comparing this transcript to the original webinar call currently on record, I can say that the transcript is significantly "corrupted" with much information changed, watered-down, or completely left out. Whoever transcribed and posted this transcript on Yahoo appears to be trying to 'skew" the dialogue, as witnessed by the lack of any reference to the Scientific Translational Medicine reported findings of Mayo Clinic's Dr, Vile in CAR-T therapy and the work of a Big Pharma company, using their own CAR-T constructs to reproduce the work of Dr. Vile and the Mayo Clinic. The same Big Pharma is running a second study to reproduce their first findings as further stated by Andrew de Guttadauro. No mention of Mayo, or Dr. Vile, or those interested CAR-T parties running their own studies with pelareorep, or other important facts in this transcript, including Matt Coffey's milestones at ASCO and post-ACO, and the omission of Q&A participant questions and responses, along with those involving Cantor Fitzgerald Louise Chen's questions in the Q&A section, as several major examples of omissions. No mention of IND-213's heavily pre-treated population which has a doubling of OS with pelareorep and the desire to see a dramatic improvement with avelumab beyond the one year survival with pelareorep to rationalize the additonal cost of that drug that ONCY would need to fully fund in an upcoming study now that Pfizer has returned avelumab to MerckKGaA and is no longer funding its development (Pfizer is developing its own CPI known as sasaslimab). That said a Phase III registration study would be a relatively straightforward comparative 2 arm study with paciltaxel (control) vs paclitaxel/pelareorep +/- avelumab and powered appropriately for OS and possibly PFS as an endpoint So instead to relying on the nonsense of this 'pseudo-transcript' posted on Yahoo for what was said and questions asked, I suggest that you listen to the webcast posted on ONCY's website.
https://www.oncolyticsbiotech.com/press-releases/detail/597/oncolytics-biotech-reports-first-quarter-2023-financial